Gottlieb Plans to Remove Barriers to Generics Competition in a Bid to Lower Prices

Drug Industry Daily
FDA Commissioner Scott Gottlieb outlined an action plan to remove barriers to generic competition, saying agency regulations have been “gamed” by brand-name manufacturers to delay generic drug approvals even after patents and exclusivity periods lapse.

To View This Article:


Subscribe To Drug Industry Daily